TCA plasma concentration and adverse effects.conjugated estrogens, vaginalconjugated estrogens, vaginal, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.desfluranedesflurane, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.dexmethylphenidatedexmethylphenidate increases effects of doxepin by decreasing metabolism. Minor/Significance Unknown.diphenhydraminediphenhydramine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.dronedaronedronedarone will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.duloxetineduloxetine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.estradiolestradiol, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens conjugated syntheticestrogens conjugated synthetic, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.estrogens esterifiedestrogens esterified, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.estropipateestropipate, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.ethanolethanol, doxepin. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.ethinylestradiolethinylestradiol, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.etomidateetomidate, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.eucalyptusdoxepin and eucalyptus both increase sedation. Minor/Significance Unknown.fluphenazinedoxepin, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.glimepiridedoxepin increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.glipizidedoxepin increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.glyburidedoxepin increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.hydroxyprogesterone caproate (DSC)hydroxyprogesterone caproate (DSC), doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.insulin aspartdoxepin increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.insulin detemirdoxepin increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.insulin glarginedoxepin increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.insulin glulisinedoxepin increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.insulin lisprodoxepin increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.insulin NPHdoxepin increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.insulin regular humandoxepin increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.isoproterenolisoproterenol, doxepin. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.ketamineketamine, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.lithiumlithium, doxepin. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.maravirocmaraviroc will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.marijuanamarijuana will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.mestranolmestranol, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.metformindoxepin increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.miglitoldoxepin increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.nateglinidedoxepin increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.panax ginsengpanax ginseng increases effects of doxepin by pharmacodynamic synergism. Minor/Significance Unknown.parecoxibparecoxib will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.pentobarbitalpentobarbital, doxepin. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.perphenazineperphenazine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.doxepin, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.phenobarbitalphenobarbital, doxepin. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.pioglitazonedoxepin increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.pleurisy rootpleurisy root decreases effects of doxepin by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.primidoneprimidone, doxepin. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.prochlorperazinedoxepin, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.progesterone micronizedprogesterone micronized, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.promazinedoxepin, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.promethazinedoxepin, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.propofolpropofol, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.quinacrinequinacrine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.ranolazineranolazine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.repaglinidedoxepin increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.rosiglitazonedoxepin increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.sagedoxepin and sage both increase sedation. Minor/Significance Unknown.saxagliptindoxepin increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.secobarbitalsecobarbital, doxepin. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.serdexmethylphenidate/dexmethylphenidateserdexmethylphenidate/dexmethylphenidate increases effects of doxepin by decreasing metabolism. Minor/Significance Unknown.sertralinesertraline will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.sevofluranesevoflurane, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.sitagliptindoxepin increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.sulfamethoxazolesulfamethoxazole decreases levels of doxepin by unspecified interaction mechanism. Minor/Significance Unknown.thioridazinedoxepin, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.tipranavirtipranavir will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Minor/Significance Unknown.tolazamidedoxepin increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamidedoxepin increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.trifluoperazinedoxepin, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.doxepin, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.vasopressindoxepin increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.verapamilverapamil increases levels of doxepin by decreasing metabolism. Minor/Significance Unknown.vildagliptindoxepin increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.zolpidemzolpidem, doxepin. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.5-HTPMonitor Closely (1)doxepin and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.abametapirSerious - Use Alternative (1)abametapir will increase the level or effect of doxepin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.abirateroneMonitor Closely (1)abiraterone increases levels of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of doxepin by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .acarboseMinor (1)doxepin increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)aclidinium and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.acrivastineMonitor Closely (1)acrivastine and doxepin both increase sedation. Use Caution/Monitor.albuterolMonitor Closely (2)doxepin and albuterol both increase QTc interval. Use Caution/Monitor. doxepin increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)doxepin, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.alfentanilMonitor Closely (1)alfentanil and doxepin both increase sedation. Use Caution/Monitor.alfuzosinMonitor Closely (1)doxepin and alfuzosin both increase QTc interval. Use Caution/Monitor.almotriptanMonitor Closely (1)almotriptan and doxepin both increase serotonin levels. Modify Therapy/Monitor Closely.alprazolamMonitor Closely (1)alprazolam and doxepin both increase sedation. Use Caution/Monitor.amifampridineMonitor Closely (1)doxepin increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.amiodaroneMonitor Closely (1)amiodarone will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)doxepin and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.amisulprideMonitor Closely (1)doxepin and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.amitriptylineMonitor Closely (2)amitriptyline and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor. amitriptyline and doxepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amitriptyline and doxepin both increase QTc interval. Avoid or Use Alternate Drug. amitriptyline and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.amobarbitalMonitor Closely (1)amobarbital and doxepin both increase sedation. Use Caution/Monitor.Minor (1)amobarbital, doxepin. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.amoxapineMonitor Closely (2)amoxapine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor. amoxapine and doxepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amoxapine and doxepin both increase QTc interval. Avoid or Use Alternate Drug. amoxapine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.anagrelideMonitor Closely (1)doxepin and anagrelide both increase QTc interval. Use Caution/Monitor.anticholinergic/sedative combosMonitor Closely (1)anticholinergic/sedative combos and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.apomorphineMonitor Closely (2)doxepin and apomorphine both increase sedation. Use Caution/Monitor. doxepin and apomorphine both increase QTc interval. Use Caution/Monitor.arformoterolMonitor Closely (2)doxepin increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. doxepin and arformoterol both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)doxepin, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.aripiprazoleMonitor Closely (2)aripiprazole and doxepin both increase sedation. Use Caution/Monitor. doxepin and aripiprazole both increase QTc interval. Use Caution/Monitor.armodafinilMonitor Closely (1)doxepin increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.arsenic trioxideSerious - Use Alternative (1)doxepin and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.artemetherSerious - Use Alternative (1)doxepin and artemether both increase QTc interval. Avoid or Use Alternate Drug.artemether/lumefantrineSerious - Use Alternative (2)doxepin and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. artemether/lumefantrine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.asenapineMonitor Closely (3)asenapine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. doxepin and asenapine both increase QTc interval. Use Caution/Monitor. asenapine and doxepin both increase sedation. Use Caution/Monitor.asenapine transdermalMonitor Closely (2)asenapine transdermal and doxepin both increase QTc interval. Use Caution/Monitor. asenapine transdermal and doxepin both increase sedation. Use Caution/Monitor.atazanavirMonitor Closely (1)atazanavir increases levels of doxepin by unspecified interaction mechanism. Use Caution/Monitor.atomoxetineMonitor Closely (1)doxepin and atomoxetine both increase QTc interval. Use Caution/Monitor.atracuriumMonitor Closely (1)atracurium and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineMonitor Closely (1)atropine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.Minor (1)doxepin increases levels of atropine by unknown mechanism. Minor/Significance Unknown.atropine IV/IMMonitor Closely (1)atropine IV/IM and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.Minor (1)doxepin increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.avapritinibMonitor Closely (1)avapritinib and doxepin both increase sedation. Use Caution/Monitor.azelastineMonitor Closely (1)azelastine and doxepin both increase sedation. Use Caution/Monitor.azithromycinMonitor Closely (1)doxepin and azithromycin both increase QTc interval. Use Caution/Monitor.baclofenMonitor Closely (1)baclofen and doxepin both increase sedation. Use Caution/Monitor.bazedoxifene/conjugated estrogensMinor (1)bazedoxifene/conjugated estrogens, doxepin. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.bedaquilineMonitor Closely (1)doxepin and bedaquiline both increase QTc interval. Use Caution/Monitor.belladonna alkaloidsMonitor Closely (1)belladonna alkaloids and doxepin both decrease cholinergic effects/transmission.